Oxford Biomedica Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	168.74	128.8	89.54	139.99	142.8
Revenue Growth (YoY)	31.01%	43.84%	-36.04%	-1.97%	62.77%
Cost of Revenue	102.76	75.78	49.81	70.81	60.16
Gross Profit	65.98	53.02	39.73	69.18	82.64
Selling, General & Admin	93.16	92.84	116.97	23.12	13.95
Research & Development	5.06	4.54	11.47	94.82	47.42
Other Operating Expenses	-1.14	-3.53	-2.8	-2.31	-0.87
Operating Expenses	97.08	93.85	125.64	115.64	60.51
Operating Income	-31.1	-40.83	-85.91	-46.46	22.13
Interest Expense	-13.86	-9.84	-10.67	-8.69	-0.86
Interest & Investment Income	2.38	3.24	4.91	0.97	-
Currency Exchange Gain (Loss)	2.81	-0.62	1.94	-7.98	-
Other Non Operating Income (Expenses)	-0.77	-0.67	-0.53	-0.07	-0.03
EBT Excluding Unusual Items	-40.55	-48.72	-90.26	-62.21	21.25
Merger & Restructuring Charges	-1.3	-0.2	-	-5.1	-1.2
Gain (Loss) on Sale of Assets	-	-0.07	1.02	21.39	-
Asset Writedown	-	-	-99.28	-0.05	-0.17
Other Unusual Items	9.92	1.72	-	-	-
Pretax Income	-31.94	-47.27	-188.53	-45.98	19.88
Income Tax Expense	-1.29	1.34	-4.37	-0.82	0.87
Earnings From Continuing Operations	-30.65	-48.61	-184.16	-45.16	19.01
Minority Interest in Earnings	0.52	5.42	26.67	6	-
Net Income	-30.13	-43.19	-157.49	-39.16	19.01
Net Income to Common	-30.13	-43.19	-157.49	-39.16	19.01
Shares Outstanding (Basic)	112	103	97	95	83
Shares Outstanding (Diluted)	112	103	97	95	86
Shares Change (YoY)	8.18%	7.15%	1.82%	10.76%	7.10%
EPS (Basic)	-0.27	-0.42	-1.63	-0.41	0.23
EPS (Diluted)	-0.27	-0.42	-1.63	-0.41	0.22
Free Cash Flow	-4.25	-58.16	-38.35	-28.91	15.99
Free Cash Flow Per Share	-0.04	-0.56	-0.40	-0.30	0.19
Gross Margin	39.10%	41.17%	44.37%	49.42%	57.87%
Operating Margin	-18.43%	-31.70%	-95.95%	-33.19%	15.50%
Profit Margin	-17.85%	-33.53%	-175.89%	-27.97%	13.31%
Free Cash Flow Margin	-2.52%	-45.16%	-42.83%	-20.65%	11.20%
EBITDA	-18.26	-23.91	-70.01	-31.1	32.66
EBITDA Margin	-10.82%	-18.56%	-78.19%	-22.22%	22.87%
D&A For EBITDA	12.84	16.92	15.9	15.36	10.53
EBIT	-31.1	-40.83	-85.91	-46.46	22.13
EBIT Margin	-18.43%	-31.70%	-95.95%	-33.19%	15.50%
Effective Tax Rate	-	-	-	-	4.37%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.